Tag Archive for: New Data

4SC: Landmark RESMAIN study data presented at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting

/in

Maintenance therapy is now clinically proven to postpone disease progression in advanced CTCL which could significantly change current clinical practice RESMAIN is one of the largest clinical trials in cutaneous T-cell lymphoma (CTCL) to-date Resminostat (Kinselby) as a maintenance treatment for advanced CTCL, is clinically proven to postpone disease progression in patients – a new treatment […]

Read more

4SC: RESMAIN study data to be presented at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting

/in

Planegg-Martinsried, Germany, 15 September 2023 – 4SC AG (4SC, FSE Prime Standard: VSC), a biotech company improving the lives of patients suffering with advanced-stage cutaneous T-cell lymphoma (CTCL), today announced that renowned dermato-oncology key opinion leader and study investigator, Professor Rudolf Stadler, University Hospital Johannes Wesling, Minden, Germany, will give an oral presentation on the findings from […]

Read more

Tim Xu discusses new data from Amplyx

/in

Phase 2 data from Arix portfolio company Amplyx and why anti-infectives are especially important now during the pandemic.

Read more